Abstract:Protein Arginine Methyltransferases (PRMTs) are a family of enzymes regulating protein arginine methylation, which is a post-translational modification crucial for various cellular processes. Recent studies have highlighted the mechanistic role of PRMTs in cancer pathogenesis, immunotherapy, and drug resistance. PRMTs are involved in diverse oncogenic processes, including cell proliferation, apoptosis, and metastasis. They exert their effects by methylation of histones, transcription factors, and other regulatory proteins, resulting in altered gene expression patterns. PRMT-mediated histone methylation can lead to aberrant chromatin remodeling and epigenetic changes that drive oncogenesis. Additionally, PRMTs can directly interact with key signaling pathways involved in cancer progression, such as the PI3K/Akt and MAPK pathways, thereby modulating cell survival and proliferation. In the context of cancer immunotherapy, PRMTs have emerged as critical regulators of immune responses. They modulate immune checkpoint molecules, including programmed cell death protein 1 (PD-1), through arginine methylation. Drug resistance is a significant challenge in cancer treatment, and PRMTs have been implicated in this phenomenon. PRMTs can contribute to drug resistance through multiple mechanisms, including the epigenetic regulation of drug efflux pumps, altered DNA damage repair, and modulation of cell survival pathways. In conclusion, PRMTs play critical roles in cancer pathogenesis, immunotherapy, and drug resistance. In this overview, we have endeavored to illuminate the mechanistic intricacies of PRMT-mediated processes. Shedding light on these aspects will offer valuable insights into the fundamental biology of cancer and establish PRMTs as promising therapeutic targets.

Hetero-oligomeric interaction as a new regulatory mechanism for protein arginine methyltransferases

Oligomerization of protein arginine methyltransferase 1 and its effect on methyltransferase activity and substrate specificity

Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)

Independent transcriptomic and proteomic regulation by type I and II protein arginine methyltransferases

Molecular Mechanism underlying PRMT1 Dimerization for SAM Binding and Methylase Activity

Intrafamily heterooligomerization as an emerging mechanism of methyltransferase regulation

Theoretical insights into catalytic mechanism of protein arginine methyltransferase 1

Structure, Function, and Activity of Small Molecule and Peptide Inhibitors of Protein Arginine Methyltransferase 1

Chemical probes and methods for the study of protein arginine methylation

The regulation, functions and clinical relevance of arginine methylation

The Novel Protease Activities of JMJD5–JMJD6–JMJD7 and Arginine Methylation Activities of Arginine Methyltransferases Are Likely Coupled

Protein arginine methylation of non-histone proteins and its role in diseases.

The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond

A systematic survey of PRMT interactomes reveals the key roles of arginine methylation in the global control of RNA splicing and translation

Dysregulation of arginine methylation in tumorigenesis

Proteomics Profiling of Arginine Methylation Defines PRMT5 Substrate Specificity

The Where and the How of PRMT5

ETD-Based Proteomic Profiling Improves Arginine Methylation Identification and Reveals Novel PRMT5 Substrates

Protein Arginine Methyltransferases (PRMTs): Orchestrators of Cancer Pathogenesis, Immunotherapy Dynamics, and Drug Resistance

The Role of PRMT1 in Cellular Regulation and Disease: Insights into Biochemical Functions and Emerging Inhibitors for Cancer Therapy

Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation